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group of 95 patients was included in the final group under examination: 90 patients (mean age: 61.2+/-18.3 years; 54% men; 19% inpatient) had not received antibiotic prophylaxis before ERCP and 5 patients (mean age: 39.2+/-18.1 years; 60% men; 60% inpatient) had received it.
Study design
This was a retrospective case-control study, carried out in a single centre. The length of follow-up was seven days and only patients whose follow-up data were available were selected and included in the analysis, thus no loss to follow-up was reported.
Analysis of effectiveness
All patients included in the initial sample were taken into account in the effectiveness study. The primary outcomes estimated in the analysis were endoscopic endpoints, such as biliary structure, choledocholithiasis, primary sclerosis cholangitis, other results, no obstruction, unsuccessful cannulation of common bile duct (CBD), successful drainage, stone extraction, sphincterotomy, and placement of endoprosthesis. Comparability of study groups was not reported, but baseline characteristics appear to have been quite different between the two groups in terms of age and inpatient status.
Effectiveness results
The effectiveness results were as follows:
biliary structure occurred in 62% of patients in the no antibiotic prophylaxis group and 20% of patients in the antibiotic prophylaxis group; choledocholithiasis occurred in 16% of patients in the no antibiotic prophylaxis group and 60% of patients in the antibiotic prophylaxis group; primary sclerosis cholangitis occurred in 7% of patients in the no antibiotic prophylaxis group and 20% of patients in the antibiotic prophylaxis group; other results occurred in 3% of patients in the no antibiotic prophylaxis group and 0 of patients in the antibiotic prophylaxis group; no obstruction occurred in 7% of patients in the no antibiotic prophylaxis group and 0 patients in the antibiotic prophylaxis group; unsuccessful cannulation of CBD occurred in 5% of patients in the no antibiotic prophylaxis group and 0 patients in the antibiotic prophylaxis group; successful drainage rate was 90% of patients in the no antibiotic prophylaxis group and 100% of patients in the antibiotic prophylaxis group; stone extraction occurred in 13% of patients in the no antibiotic prophylaxis group and 60% of patients in the antibiotic prophylaxis group; sphincterotomy was performed in 26% of patients in the no antibiotic prophylaxis group and 40% of patients in the antibiotic prophylaxis group; and placement of endoprosthesis occurred in 62% of patients in the no antibiotic prophylaxis group and 40% of patients in the antibiotic prophylaxis group.
Clinical conclusions
The effectiveness analysis, which was intended to provide probability values of events considered in the decision model, showed that none of the patients in the group receiving antibiotic prophylaxis developed cholangitis, while a few
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Modelling
A decision tree model was constructed to model clinical outcomes and costs of ERCP performed with or without antibiotic prophylaxis. A hypothetical cohort of 100 patients with obstructive jaundice either received or did not receive antibiotic prophylaxis prior to ERCP and then developed cholangitis or other complications. The probabilities used in the decision model were derived from the literature and from the single study.
Outcomes assessed in the review
The primary health outcomes (model inputs) were the probabilities of the following events: cholangitis with prophylaxis, cholangitis without prophylaxis, complications from ERCP and percutaneous transhepatic cholangiography (PTC), death from cholangitis, and death from complications from ERCP and PTC.
Study designs and other criteria for inclusion in the review
Three of the primary studies included in the review were randomised controlled trials.
Sources searched to identify primary studies
The MEDLINE database was searched to identify relevant primary studies using the terms "ERCP", "biliary obstruction", "cholangitis", "antibiotic", "prophylaxis", and "antibiotic prophylaxis". The references found via MEDLINE were then used to identify further studies.
Criteria used to ensure the validity of primary studies
Not stated.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Six primary studies were used as the source of effectiveness.
Methods of combining primary studies
Primary studies were combined using narrative methods.
Investigation of differences between primary studies
Not carried out.
Results of the review
The probability values were 0.0549 for cholangitis with prophylaxis, 0.0661 for cholangitis without prophylaxis, 0.05 for complications from ERCP and 0.18 for complications from PTC, 0.1 for death from cholangitis, and 0.025 for death from complications from ERCP and 0.051 for death from complications from PTC.
Methods used to derive estimates of effectiveness
The authors made an assumption used in the decision model.
Direct costs
Discounting was not performed, as the time horizon of the study was short. Unit costs were not reported separately from quantities of resources used. The health service costs included in the analysis were antibiotics, cholangitis, management of complications of ERCP, ERCP, PTC, and management of antibiotic side effects. The cost/resource boundary adopted was that of the third party payer. The estimation of costs was based on actual data, derived from average wholesale prices for drugs, and average Medicare reimbursement rates at the authors' institution for the remaining items. The cost of management of antibiotic side effects was based on authors' assumptions. Total costs were obtained using modelling. Neither source nor dates for resource use were reported. The price year was 2000.
Statistical analysis of costs
Costs were treated deterministically.
Indirect Costs
Indirect costs were not included in the analysis.
Currency

US dollars ($).
Sensitivity analysis
One-way and two-way sensitivity analyses were conducted to assess the robustness of the estimated costs to variations in the following model inputs: probability of cholangitis with antibiotic prophylaxis, probability of cholangitis without antibiotic prophylaxis, probability of severe antibiotic reaction, cost of antibiotic and cost of cholangitis.
Estimated benefits used in the economic analysis
When data from the literature were used, the expected episodes of cholangitis per 100 patients were 5 in the group of those receiving antibiotic prophylaxis and 6 among those who did not receive antibiotic prophylaxis, and the expected number of deaths due to cholangitis was 0.5 when antibiotic prophylaxis was performed prior to ERCP and 0.6 in patients who did not receive antibiotic prophylaxis.
When data from the single study were used, the expected episodes of cholangitis per 100 patients were 0 in the group of those receiving antibiotic prophylaxis and 3 among those who did not receive antibiotic prophylaxis, while the expected number of deaths due to cholangitis was 0 when antibiotic prophylaxis was performed prior to ERCP and 0.3 in patients who did not receive antibiotic prophylaxis.
